Pendergrast W J, Drake W P, Mardiney M R
J Natl Cancer Inst. 1975 Nov;55(5):1223-5. doi: 10.1093/jnci/55.5.1223.
The therapeutic efficacy of polyadenlyic-polyuridylic acid (poly A-poly U) on the transplantable AKR leukemia varied with the dose of tumor cells implanted. The greater the number of AKR tumor cells injected into 8-week-old AKR mice free of clinical evidence of cancer, the greater the effect of poly A-poly U in mediating host immunologic control of the tumor. Poly A-poly U was either ineffective or could enhance tumor growth when smaller doses of tumor cells were transferred. The efficacy of an immune adjuvant depended on a tumor burden affording optimum host responsiveness. This does not necessarily arise in the host bearing minimal tumor burden.
聚腺苷酸-聚尿苷酸（聚A-聚U）对可移植性AKR白血病的治疗效果随植入肿瘤细胞的剂量而变化。将AKR肿瘤细胞注入无癌症临床证据的8周龄AKR小鼠体内，注入的肿瘤细胞数量越多，聚A-聚U在介导宿主对肿瘤的免疫控制方面的效果就越大。当转移较小剂量的肿瘤细胞时，聚A-聚U要么无效，要么会促进肿瘤生长。免疫佐剂的疗效取决于能使宿主产生最佳反应的肿瘤负荷。在肿瘤负荷最小的宿主中不一定会出现这种情况。
